B7-H3 CAR-T cell therapy combined with irradiation is effective in targeting bulk and radiation-resistant chordoma cancer cells.

ABSTRACT:

Background

Chordoma is a slow-growing, primary malignant bone tumor that arises from notochordal tissue in the midline of the axial skeleton. Surgical excision with negative margins is the mainstay of treatment, but high local recurrence rates are reported even with negative margins. High-dose radiation therapy (RT), such as with proton or carbon ions, has been used as an alternative to surgery, but late local failure remains a problem. B7-H3 is an immune checkpoint, transmembrane protein that is dysregulated in many cancers, including chordoma. This study explores the efficacy of B7-H3 chimeric antigen receptor T (CAR-T) therapy in vitro and in vivo.

Methods

Chordoma cancer stem cells (CCSCs) were identified using flow cytometry, sphere formation, and western blot analysis.

SUBMITTER: Wang K 

PROVIDER: S-EPMC11784168 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature